Clinical Trials
11 trialsNCT05176483 2026-05-27
STELLAR-002
Exelixis
Phase 1 Recruiting
NCT03044613 2026-03-23
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT04697576 2026-03-10
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT04658147 2025-12-18
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT04935229 2025-10-22
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
TriSalus Life Sciences, Inc.
Phase 1 Terminated
NCT02966548 2025-02-17
Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT03493932 2024-07-24
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03978611 2024-07-24
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
Bristol-Myers Squibb
Phase 1 Terminated
NCT05498480 2024-02-20
RELATIVITY-111
Bristol-Myers Squibb
Phase 1 Completed
NCT04112498 2023-04-06
A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
Bristol-Myers Squibb
Phase 1 Completed
NCT03335540 2022-09-26
ADVISE
Bristol-Myers Squibb
Phase 1 Completed